Deborah Zihler
Kantonsspital Aarau(CH)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Bladder and Urothelial Cancer Treatments, Testicular diseases and treatments, Melanoma and MAPK Pathways
Most-Cited Works
- → Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study(2016)197 cited
- → Age‐ and Gender‐Dependent Left Ventricular Remodeling(2013)73 cited
- → BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin’s lymphoma from primary mediastinal large B‐cell lymphoma(2009)72 cited
- → Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial(2022)58 cited
- → Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17(2023)42 cited
- → Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).(2020)32 cited
- → The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study(2023)16 cited
- → Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.(2022)14 cited
- → Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.(2021)12 cited
- → Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment(2023)11 cited